Arbutus Biopharma Corp. and Genevant Sciences GmbH have won a preliminary round in their patent infringement suit against Moderna Inc. over COVID-19 vaccine technology.

Pennsylvania U.S. District Judge Mitchell Goldberg, sitting by designation in Delaware, on Wednesday turned away Moderna’s bid to move most of the case to the Court of Federal Claims and make the U.S. government the defendant.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]